FDA拟为NAC设立新监管类别,确立其膳食补充剂身份
STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC
FDA正提议为N-乙酰-L-半胱氨酸(NAC)设立新的监管分类,将其列为首个"未被排除于膳食补充剂定义之外"的成分。NAC此前已被FDA分别于1963年和1985年批准作为药物使用,但依据现有法规,获批药物不得同时归入膳食补充剂类别。该拟议规则标志着NAC首次获得明确的膳食补充剂法律地位。
WASHINGTON — The Food and Drug Administration is proposing a new classification for a product that’s existed in a legal gray area for years, a win for proponents of dietary supplements, including members of the MAHA movement.
The proposed rule would classify N-acetyl-L-cysteine, known as NAC and already widely sold over the counter, as the agency’s first “Dietary Ingredient Not Excluded from the Dietary Supplement Definition” — in essence, not not a supplement.
The need for the legal backbending stems from the fact that the FDA previously approved NAC as a drug, and FDA regulations prohibit the agency from including approved drugs in the dietary supplement category. In 1963, the agency approved NAC to break up mucus in certain lung conditions, and in 1985 to treat acetaminophen overdose.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com